Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-10-12 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2021年股票期权激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is a detailed list of stock option incentive plan recipients for the year 2021, including names, positions, and allocation details. It does not contain financial statements, earnings data, or regulatory certifications. It is not an announcement of a report but a disclosure of stock option incentive allocations to management and core personnel. This type of document relates to disclosures about management incentives and share-based compensation plans, which typically fall under Remuneration Information filings. The document is not a proxy statement or voting result announcement, nor is it a general regulatory filing or capital change announcement. Therefore, the best fitting category is Remuneration Information (DEF 14A).
2021-10-12 Chinese
君泽君关于特一药业2021年股票期权激励计划的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a 2021 stock option incentive plan of a listed company, 特一药业集团股份有限公司. It discusses the legal compliance, procedures, and qualifications related to the stock option plan, including references to company law, securities law, and regulatory requirements. The document is not a financial report, earnings release, or management discussion, but a legal opinion on a capital incentive plan. It is not an announcement of a report but a substantive legal opinion document. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to stock option incentive plans which affect the company's capital structure and financing arrangements.
2021-10-12 Chinese
上市公司股权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a compliance self-check form related to a company's equity incentive plan, listing various compliance criteria and confirmations. It is a regulatory or compliance checklist rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is under 5,000 characters and it is a form confirming compliance with regulatory requirements for equity incentive plans. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related filing without substantive financial data or report content.
2021-10-12 Chinese
2021年第一次临时股东大会资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2021 First Extraordinary General Meeting" of Teyi Pharmaceutical Group Co., Ltd. It contains proposals related to a stock option incentive plan, including the draft plan, implementation management methods, and authorization for the board to handle related matters. The content is clearly intended for shareholder review and voting at a general meeting. The document is relatively short (2769 characters) and consists of meeting materials rather than the minutes or voting results. It is not a full report, financial statement, or earnings release. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2021-10-12 Chinese
关于第四届董事会第二十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of 特一药业集团股份有限公司. It details the approval of a stock option incentive plan draft, its implementation management measures, and authorization requests to the shareholders' meeting. It also announces the scheduling of an extraordinary shareholders' meeting to consider these matters. The document is a formal announcement of board decisions and meeting arrangements, not a full report or financial statement. It does not contain financial data or detailed financial analysis. The document length is 3276 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-10-12 Chinese
关于公司药品吡嗪酰胺片通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (吡嗪酰胺片) passing a consistency evaluation by the National Medical Products Administration. It includes details about the drug, regulatory approval, and the impact on the company. The document is short (1220 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event related to the company's product, not a financial report or management discussion. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-08 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.